Loading...

Home
ETF
PGEN

PGEN

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

PGEN News

Precigen Announces PAPZIMEOS as New Standard of Care for RRP Treatment

Jan 20 2026PRnewswire

Precigen Receives FDA Approval for PAPZIMEOS, Surpassing 200 Patient Registrations

Jan 12 2026Newsfilter

Precigen CEO Helen Sabzevari to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 05 2026PRnewswire

Ultragenyx Shares Plunge 42% Following Phase 3 Study Failures for Setrusumab

Dec 29 2025Benzinga

DigitalBridge Group Inc Acquired by SoftBank Group for Approximately $4 Billion

Dec 29 2025Benzinga

Promega Collaborates with Oxford to Accelerate Precision Medicine Research

Dec 09 2025Businesswire

HC Wainwright & Co. Reaffirms Buy Rating for Precigen (PGEN)

Nov 15 2025NASDAQ.COM

Purchase Precigen at $3.50 and Achieve 27.1% Returns Through Options

Nov 14 2025NASDAQ.COM

Biotech Stocks Rise for Vaxart and Precigen Following Q3 Earnings Reports

Nov 14 2025SeekingAlpha

Earnings Report for November 13, 2025: After-Hours Updates on AMAT, BAP, STN, GLOB, TMC, TRVI, PGEN, BZH, OMER, TBN, TOI, AIRJ

Nov 13 2025NASDAQ.COM

Precigen Reports Third Quarter 2025 Financial Results and Business Updates

Nov 13 2025PRnewswire

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

Nov 06 2025PRnewswire

Patient Capital Makes Significant Investment in Precigen (PGEN) with Purchase of 10.2 Million Shares

Nov 01 2025NASDAQ.COM

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Oct 13 2025PRnewswire

Two Healthcare Stocks Have Recently More Than Doubled and May Rise Even Further, Say Wall Street Analysts

Sep 07 2025NASDAQ.COM

Precigen Obtains $125 Million Credit Facility from Pharmakon to Propel PAPZIMEOS Commercialization

Sep 03 2025NASDAQ.COM